Mtbvac is the first vaccine against the variant of the disease that affects humans, according to a statement from the Indian company Bharat Biotech International Ltd.

The trial began after completing a previous dose escalation trial in HIV-uninfected people and this new phase is aimed at determining whether Mtbvac is safe in the human immunodeficiency virus-infected population.

The results are expected to be a milestone in global vaccinology and an example of public-private, national and international collaboration.

In statements to reporters, Biofabri CEO Esteban Rodriguez called it a giant step forward to test adults and adolescents in India, where 28 percent of the world’s tuberculosis cases are reported, he said.

Krishna Ella, executive chairman of Bharat Biotech, said that the search for a more effective TB vaccine gets a big boost from clinical trials in India.

He also considered the partnership with the Spanish company a noble endeavor, as part of collaboration to reinvent TB vaccines.

jg/arm/ro/lr